Author

S. Senturk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

G. Karakulah· 3 shared A. Eray· 2 shared S. Erkek Ozhan· 2 shared A. Aribas· 1 shared A. Bursali· 1 shared A. Cakir· 1 shared A. G. O. Demir· 1 shared A. Kisim· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. Karakulah

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Retinoids and EZH2 inhibitors cooperate to orchestrate cytotoxic effects on bladder cancer cells

G. Ozgun, T. Yaras, N. Landman, G. Karakulah, M. M. S. van Lohuizen, S. Senturk, S. Erkek Ozhan

This study shows that combining retinoids and EZH2 inhibitors enhances cytotoxic effects on bladder cancer cells by promoting apoptosis, cell cycle arrest, and anti-oncogenic gene expression.

bioRxiv · Apr 19, 2023 · PreprintCancer Biology

Differential occupancy and regulatory interactions of KDM6A in bladder cell lines

G. Ozden-Yilmaz, B. Savas, A. Bursali, A. Eray, A. Aribas, S. Senturk, E. Karaca, G. Karakulah, S. Erkek-Ozhan

This study examines KDM6A occupancy and regulatory interactions in bladder cells, revealing differential binding patterns and potential interactors in normal and cancer settings.

Cells · Mar 8, 2023Peer-reviewedCancer Biology

Hexokinase 1b is a novel target for non-small-cell lung cancer

Y. Yozgat, E. Karakoc, O. Sahin, S. Cimen, W. M. Rabeh, M. S. Aydin, A. Mardinoglu, I. Gursel, A. Cakir, O. Sensoy, E. M. Ozdemir, Y. Bayrak, M. Z. Gunluoglu, O. Saatci, J. Jabbar, , M. A. Cevher

This study identifies HK1b as a novel therapeutic target in NSCLC by showing its role in glycolysis, tumor progression, and cisplatin resistance.

bioRxiv · Jun 27, 2022 · PreprintCancer Biology

FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer

P. Y. Guneri Sozeri, G. Ozden Yilmaz, A. Kisim, E. Cakiroglu, A. Eray, H. Uzuner, G. Karakulah, D. Pesen Okvur, S. Senturk, S. Erkek Ozhan

This study identifies FRA1 and FLI1 as key transcription factors driving the regulatory networks in muscle invasive bladder cancer, showing their role in EMT and invasion.

bioRxiv · Nov 22, 2021Cancer Biology

An epigenetic switch regulates the ontogeny of AXL positive/EGFR-TKI resistant cells by modulating miR-335 expression

R. Sordella, D. Pal, P. Safaric Tepes, T. Lindsted, I. Ibarra, A. Lujambio, V. Jimenez Sabinina, S. Senturk, M. Miller, N. Korimerla, J. Huang, L. Glassman, P. Lee, D. Zeltsman, K. Hyman, , G. Hannon

The paper identifies an epigenetic mechanism regulating AXL-positive/Erlotinib-resistant cells through miR-335 expression, suggesting combinatorial therapies for EGFR-mutated NSCLC.

bioRxiv · Jan 6, 2021Cancer Biology